In human pancreatic adenocarcinoma, hypomethylation of the Aqp5 gene promoter accounted for its high expression associated with infiltrating immune cells, suggesting Aqp5 may represent a novel prognostic biomarker and a new immune-associated therapeutic target for patients suffering from such cancer [114]. The gene discussed is AQP5; the disease is pancreatic adenocarcinoma.